替普瑞酮治疗慢性萎缩性胃炎66例疗效分析

Clinical effect discussion of teprenone in treatment of 66 cases with chronic atrophic gastritis

目的探究替普瑞酮治疗慢性萎缩性胃炎的临床疗效。方法择取我院2012年4月~2014年2月66例慢性萎缩性胃炎患者,将其按照数字表法随机分组,分别为对照组（33例）和观察组（33例）,其中给予对照组患者枸橼酸铋钾治疗,观察组患者给予替普瑞酮治疗,比较两组患者的症状评分、Hp根除率以及治疗总有效率。结果两组患者治疗后Hp根除率比较差异无统计学意义（P〉0.05）,治疗后观察组患者的治疗总有效率及症状评分均优于对照组患者,差异具有统计学意义（P〈0.05）。结论在对慢性萎缩性胃炎患者的治疗中,采取替普瑞酮治疗疗效显著,不仅可明显改善患者的临床症状,而且可提高患者的治疗效果。

Objective To explore the clinical effect of teprenone in treatment of chronic atrophic gastritis. Methods 66 cases of patients with chronic atrophic gastritis cured in our hospital from April 2012 to February 2014 were randomly divided into control group and observation group with 33 cases in each group by the digital method. Patients in the control group were treated with colloidal bismuth subcitrate, and patients in the observation group were treated with teprenone. Symptom score, Hp eradication rate and the total effective rate of the two groups were compared. Results Hp eradication rates of the two groups were not significantly different after the treatment（P〈0.05）. The total effective rate and symptom score of observation group were better than those of control group. There were significant differences（P〈0.05）. Conclusion In the treatment of patients with chronic atrophic gastritis, the clinical effect of teprenone is remarkable. It can improve the clinical symptoms and the treatment effect of patients.